Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study)
Jazyk angličtina Země Anglie, Velká Británie Médium electronic-ecollection
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
PubMed
32257246
PubMed Central
PMC7103803
DOI
10.1136/openhrt-2019-001202
PII: openhrt-2019-001202
Knihovny.cz E-zdroje
- Klíčová slova
- atrial fibrillation, quality of care and outcomes, stroke,
- MeSH
- antikoagulancia aplikace a dávkování škodlivé účinky MeSH
- antitrombiny aplikace a dávkování škodlivé účinky MeSH
- aplikace orální MeSH
- časové faktory MeSH
- cévní mozková příhoda diagnóza etiologie prevence a kontrola MeSH
- dabigatran aplikace a dávkování škodlivé účinky MeSH
- dospělí MeSH
- fibrilace síní komplikace diagnóza farmakoterapie MeSH
- krvácení chemicky indukované MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- náhrada léků MeSH
- ochranné faktory MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- spokojenost pacientů * MeSH
- vitamin K antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- zdraví - znalosti, postoje, praxe * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Izrael MeSH
- Názvy látek
- antikoagulancia MeSH
- antitrombiny MeSH
- dabigatran MeSH
- vitamin K MeSH
OBJECTIVE: We evaluated atrial fibrillation (AF) patients' perceptions of anticoagulation treatment with dabigatran or a vitamin K antagonist (VKA) for stroke prevention, according to accepted indications. METHODS: The RE-SONANCE observational, prospective, multicentre, international study used the validated Perception on Anticoagulant Treatment Questionnaire (PACT-Q) to assess patients with AF already taking a VKA who were switched to dabigatran (cohort A), and newly diagnosed patients initiated on either dabigatran or a VKA (cohort B). Visit 1 (V1) was at baseline, and visit 2 (V2) and visit 3 (V3) were at 30-45 and 150-210 days after baseline, respectively. Primary outcomes were treatment satisfaction and convenience in cohort A at V2 and V3 versus baseline, and in cohort B for dabigatran and a VKA at V2 and V3. RESULTS: The main analysis set comprised 4100 patients in cohort A and 5365 in cohort B (dabigatran: 3179; VKA: 2186). In cohort A, PACT-Q2 improved significantly (p<0.001 for all) for treatment convenience (mean change V1 vs V2=20.72; SD=21.50; V1 vs V3=24.54; SD=22.85) and treatment satisfaction (mean change V1 vs V2=17.60; SD=18.76; V1 vs V3=21.04; SD=20.24). In cohort B, mean PACT-Q2 scores at V2 and V3 were significantly higher (p<0.001 for all) for dabigatran versus a VKA for treatment convenience (V2=18.38; SE =0.51; V3=23.34; SE=0.51) and satisfaction (V2=15.88; SE=0.39; V3=19.01; SE=0.41). CONCLUSIONS: Switching to dabigatran from long-term VKA therapy or newly initiated dabigatran is associated with improved patient treatment convenience and satisfaction compared with VKA therapy.
1st Department of Cardiology Silesian Medical University Katowice Poland
1st Department of Internal Medicine Tolna County 'Balassa Janos' Teaching Hospital Szekszard Hungary
Biostatistics and Data Sciences Boehringer Ingelheim Pharmaceuticals Inc Ridgefield Connecticut USA
Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria
Cardiology Department Riga Stradins University Riga Latvia
Cardiology University and Emergency Hospital of Bucharest Bucharest Other Romania
Clalit Health Services Bonen Clinic Haifa Israel
Department of Cardiology Clinical Centre of Serbia Belgrade Serbia
Department of Cardiology General Hospital Celje Celje Slovenia
Department of Cardiology National Cardiology Hospital Sofia Bulgaria
Department of Cardiology North Estonia Medical Centre Foundation Tallinn Estonia
Faculty of Medicine in Hradec Kralové Charles University Broumov Czech Republic
Zobrazit více v PubMed
Ogilvie IM, Newton N, Welner SA, et al. . Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638–45. 10.1016/j.amjmed.2009.11.025 PubMed DOI
Camm AJ, Lip GYH, De Caterina R, et al. . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–413. 10.1093/europace/eus305 PubMed DOI
Kirchhof P, Benussi S, Kotecha D, et al. . 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78. 10.1093/europace/euw295 PubMed DOI
Steffel J, Verhamme P, Potpara TS, et al. . The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–93. 10.1093/eurheartj/ehy136 PubMed DOI
Vinereanu D, Lopes RD, Bahit MC, et al. . A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet 2017;390:1737–46. 10.1016/S0140-6736(17)32165-7 PubMed DOI
Amara W, Larsen TB, Sciaraffia E, et al. . Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace 2016;18:151–5. 10.1093/europace/euv317 PubMed DOI
Clarkesmith DE, Pattison HM, Lip GYH, et al. . Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013;8:e74037 10.1371/journal.pone.0074037 PubMed DOI PMC
Maikranz V, Siebenhofer A, Ulrich L-R, et al. . Does a complex intervention increase patient knowledge about oral anticoagulation? - a cluster-randomised controlled trial. BMC Fam Pract 2017;18:15 10.1186/s12875-017-0588-2 PubMed DOI PMC
Glauser TA, Barnes J, Nevins H, et al. . The educational needs of clinicians regarding anticoagulation therapy for prevention of thromboembolism and stroke in patients with atrial fibrillation. Am J Med Qual 2016;31:38–46. 10.1177/1062860614547363 PubMed DOI
Prins MH, Marrel A, Carita P, et al. . Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q). Health Qual Life Outcomes 2009;7:9 10.1186/1477-7525-7-9 PubMed DOI PMC
De Caterina R, Brüggenjürgen B, Darius H, et al. . Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: a PREFER in AF Registry substudy. Arch Cardiovasc Dis 2018;111:74–84. 10.1016/j.acvd.2017.04.007 PubMed DOI
Lane DA, Meyerhoff J, Rohner U, et al. . Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: results of a conjoint analysis. Clin Cardiol 2018;41:855–61. 10.1002/clc.22971 PubMed DOI PMC
Monz BU, Connolly SJ, Korhonen M, et al. . Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 2013;168:2540–7. 10.1016/j.ijcard.2013.03.059 PubMed DOI
Prins MH, Guillemin I, Gilet H, et al. . Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 2009;7:30 10.1186/1477-7525-7-30 PubMed DOI PMC
Connolly SJ, Ezekowitz MD, Yusuf S, et al. . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. 10.1056/NEJMoa0905561 PubMed DOI
Calkins H, Willems S, Gerstenfeld EP, et al. . Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627–36. 10.1056/NEJMoa1701005 PubMed DOI
Cannon CP, Lip GYH, Oldgren J. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:485–6. 10.1056/NEJMc1715183 PubMed DOI
Coleman CI, Coleman SM, Vanderpoel J, et al. . Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. J Investig Med 2013;61:878–81. 10.2310/JIM.0b013e31828df1bf PubMed DOI
Okumura Y, Yokoyama K, Matsumoto N, et al. . Patient satisfaction with direct oral anticoagulants and warfarin. Int Heart J 2018;59:1266–74. 10.1536/ihj.17-649 PubMed DOI
Prins MH, Bamber L, Cano SJ, et al. . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015;135:281–8. 10.1016/j.thromres.2014.11.008 PubMed DOI
Benzimra M, Bonnamour B, Duracinsky M, et al. . Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence 2018;12:79–87. 10.2147/PPA.S131158 PubMed DOI PMC
Keita I, Aubin-Auger I, Lalanne C, et al. . Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence 2017;11:1625–34. 10.2147/PPA.S131157 PubMed DOI PMC
Williams B, Mancia G, Spiering W, et al. . 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018;36:1953–2041. 10.1097/HJH.0000000000001940 PubMed DOI
